Comparison between systemic exposure to ciclesonide nasal spray, ciclesonide HFA nasal aerosol and orally inhaled ciclesonide (BY9010/M1-422)

Exclusion Criteria

• - Pregnancy, breast feeding, intention to become pregnant during the course of the study or lack of safe contraception in pre-menopausal women
• - Participation in any investigational drug trial within the 30 days before Screening Visit and thereafter
• - History or current clinically relevant allergies or idiosyncrasy to drugs or food
• - History of allergic reactions to any corticosteroids including ciclesonide or any excipients of the formulations
• - Any contraindication to nasally administered corticosteroids
• - History of a respiratory infection or disorder [including, but not limited to bronchitis, pneumonia, acute or chronic sinusitis, flu, severe acute respiratory syndrome (SARS)] within the 30 days before Screening Visit, or development of a respiratory infection during the Screening Period
• - History or current evidence of any other relevant allergic, cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrine, metabolic, neurological, psychiatric, or other disease within the last 2 years
• - Non-vaccinated exposure to or active infection with, chickenpox or measles within the 21 days preceding Screening Visit